CLOs on the Move

DTx Pharma

www.dtxpharma.com

 
DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Chroma Medicine

Chroma Medicine is pioneering a new class of epigenetic medicines to revolutionize treatment of genetically driven disease.

Planetrx Com

Planetrx Com is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.